Galectin Therapeutics (GALT -13.9%) is having a rough session.
The shares rose 76% late last week, as investors clamored for liver disease plays in the wake of Intercept Pharmaceuticals' monumental rally.
Today, the company announced the completion of patient enrollment "in the first cohort of a Phase 1 trial of GR-MD-02."
The study will evaluate the "safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis." (PR)